---
title: "Odyssey Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/294814294.md"
description: "Information from the Phase 2a clinical trial of the drug OD-001 has been approved for oral presentation at the upcoming United European Gastroenterology Week in October."
datetime: "2026-08-04T11:02:52.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/294814294.md)
  - [en](https://longbridge.com/en/news/294814294.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/294814294.md)
generator: "portal-rs"
---

# Odyssey Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update

Information from the Phase 2a clinical trial of the drug OD-001 has been approved for oral presentation at the upcoming United European Gastroenterology Week in October.

### Related Stocks

- [ODTX.US](https://longbridge.com/en/quote/ODTX.US.md)

## Related News & Research

- [Why Jersey Mike's stock jumped today](https://longbridge.com/en/news/298534240.md)
- [Weight Loss Trial Results Altering The Investment Case For Structure Therapeutics (GPCR)?](https://longbridge.com/en/news/298754574.md)
- [AirAsia says drug tests for all active pilots, cabin crew return negative results](https://longbridge.com/en/news/298858214.md)
- [BioNTech says lung cancer drug candidate prolonged lives in trial](https://longbridge.com/en/news/298884861.md)
- [Exelixis Stock Slips as FDA Delays Cancer Drug Review, Analyst Weighs In](https://longbridge.com/en/news/298761132.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**